$GALT

GALECTIN THERAPEUTICS INC

Galectin Therapeutics develops carbohydrate-based drug candidates that target galectin proteins, particularly galectin-3, for fibrotic diseases, cancer and selected other conditions. Its lead candidate, belapectin, is being developed for MASH cirrhosis and cancer immunotherapy, including in combination with an immune checkpoint inhibitor for head and neck cancer. The company has also completed clinical studies of belapectin in liver disease and has a small-molecule galectin-3 discovery program through its majority-owned subsidiary, Galectin Sciences LLC. Galectin Therapeutics is a clinical-stage biopharmaceutical company, and all its proposed products remain in development. It uses plant-derived starting materials to make proprietary carbohydrate compounds and develops them through preclinical and clinical programs, drawing on outside expertise in areas including manufacturing and clinical trial operations. The company seeks strategic partners as programs advance and require additional resources. It is headquartered in a suburb of Atlanta, Georgia, and maintains a laboratory operation in the Boston area.

2
1
0

No SEC Form 4 filings for $GALT in the last 30 days.

See all $GALT insider activity →
Low

Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary

Galectin Therapeutics (GALT) reported no revenue for Q3 2026, with a net loss of $3.57M, improved from $8.22M YoY. EPS loss narrowed to $0.04 from $0.13. R&D costs fell 40% due to reduced activity. The company has $11.7M in cash and expects funding through June 2027. It filed a Phase 3 protocol with the FDA and is exploring partnerships.

Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., November 16, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today

Galectin Therapeutics to present NASH cirrhosis trial data at AASLD

Galectin Therapeutics (GALT) will present data from its belapectin trials at the AASLD meeting, including a 15.9% placebo-adjusted improvement in portal hypertension risk. The company submitted a Phase 3 protocol to the FDA and is exploring partnerships. Belapectin has Fast Track designation for NASH cirrhosis treatment.

GALT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning GALT (GALECTIN THERAPEUTICS INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.

Recent GALT coverage spans earnings, technology and corporate actions.

What's driving GALT

AlphAI scores every news story that mentions GALT with an AI model for sentiment and relevance, and aggregates insider trades from GALECTIN THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GALT

Score

Galectin Therapeutics 3Q 2026: EPS ($0.04) — 10-Q Summary

Galectin Therapeutics (GALT) reported no revenue for Q3 2026, with a net loss of $3.57M, improved from $8.22M YoY. EPS loss narrowed to $0.04 from $0.13. R&D costs fell 40% due to reduced activity. The company has $11.7M in cash and expects funding through June 2027. It filed a Phase 3 protocol with the FDA and is exploring partnerships.

$GALTMedEarnings

Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., November 16, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Galectin Therapeutics (GALT) will present data on belapectin for MASH cirrhosis at AASLD Liver Meeting 2026. The company submitted a Phase 3 trial protocol to the FDA. Presentations include risk analyses from NAVIGATE and GT-026 trials, highlighting noninvasive prediction of variceal development. Galectin aims to advance belapectin as a treatment for MASH cirrhosis and portal hypertension.

Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.

$GALTMedEarnings

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reporte

Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics (NASDAQ: GALT) said Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five line-of-credit facilities into common stock effective July 31, 2026. The deal eliminated about $105.8 million of debt (about $91.0 million principal, $14.8 million interest) and issued 34,376,167 shares at a blended $3.07 conversion price. A sixth $10 million facility remains undrawn.

GALECTIN THERAPEUTICS INC (GALT): Unregistered Sales of Equity Securities

GALECTIN THERAPEUTICS INC (GALT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximatel

Related tickers